Entera Bio Ltd. WT EXP 062723 (ENTXW)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Entera Bio Ltd. WT EXP 062723 (ENTXW) with AI Score 44/100 (Weak). Entera Bio Ltd. WT EXP 062723 is a pharmaceutical company focused on developing orally delivered large molecule therapeutics. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Entera Bio Ltd. WT EXP 062723 (ENTXW) Healthcare & Pipeline Overview
Entera Bio Ltd. WT EXP 062723's warrants (ENTXW) offer exposure to the potential upside of Entera Bio's oral drug delivery technology. These warrants, expiring in June 2023, are linked to the company's efforts in developing oral formulations of large molecule therapeutics, primarily targeting osteoporosis and related bone diseases. The warrants' value is tied to Entera Bio's clinical and commercial success.
Investment Thesis
Investing in Entera Bio Ltd. WT EXP 062723 (ENTXW) is a speculative bet on the future success of Entera Bio's oral drug delivery technology. The value of these warrants, which expired in June 2023, was contingent on Entera Bio achieving key clinical and regulatory milestones. The potential upside was linked to the successful development and commercialization of its oral biologics pipeline, particularly its lead product candidate for osteoporosis. However, the warrants' expiration means they no longer hold value. Investors may want to evaluate the high-risk, high-reward nature of biotechnology investments and the specific risks associated with warrant investments.
Based on FMP financials and quantitative analysis
Key Highlights
- P/E ratio of -5.55 indicates the company is currently not profitable.
- Profit Margin of -8694.4% reflects significant losses relative to revenue.
- Gross Margin of -6.5% suggests the cost of goods sold exceeds revenue.
- The company does not offer a dividend, indicating a focus on reinvesting earnings for growth.
- Entera Bio's focus on oral delivery of large molecule therapeutics differentiates it from traditional injectable therapies.
Competitors & Peers
Strengths
- Proprietary oral drug delivery technology.
- Focus on large molecule therapeutics.
- Potential to replace injectable therapies.
- Addressing unmet needs in bone and metabolic disorders.
Weaknesses
- Negative profit margin and gross margin.
- Dependence on successful clinical trials.
- High research and development costs.
- Limited commercialized products.
Catalysts
- Upcoming: Clinical trial results for lead product candidate.
- Ongoing: Development of new oral formulations.
- Ongoing: Strategic partnerships and collaborations.
Risks
- Potential: Unsuccessful clinical trial results.
- Potential: Regulatory approval delays.
- Potential: Competition from established pharmaceutical companies.
- Ongoing: High research and development costs.
- Ongoing: Negative profit margin and gross margin.
Growth Opportunities
- Expansion into new therapeutic areas: Entera Bio can leverage its oral drug delivery platform to develop oral formulations of biologics for other indications beyond osteoporosis, such as diabetes, obesity, and inflammatory diseases. The market for oral biologics is estimated to reach $XX billion by 2030, presenting a significant growth opportunity for Entera Bio. Timeline: Ongoing.
- Strategic partnerships with pharmaceutical companies: Entera Bio can collaborate with established pharmaceutical companies to co-develop and commercialize its oral biologics. These partnerships can provide Entera Bio with access to funding, expertise, and distribution channels, accelerating the development and commercialization of its products. Timeline: Ongoing.
- Successful clinical trials and regulatory approvals: The successful completion of clinical trials and the receipt of regulatory approvals for its lead product candidate for osteoporosis will be a major growth driver for Entera Bio. Positive clinical data will validate its technology platform and increase investor confidence. Timeline: Dependent on clinical trial outcomes.
- Geographic expansion: Entera Bio can expand its geographic reach by commercializing its products in new markets, such as Europe and Asia. These markets represent significant growth opportunities, given the large patient populations and the increasing demand for innovative therapies. Timeline: 3-5 years.
- Development of next-generation oral biologics: Entera Bio can invest in research and development to develop next-generation oral biologics with improved efficacy, safety, and bioavailability. These advancements can further differentiate Entera Bio from its competitors and strengthen its market position. Timeline: 5+ years.
Opportunities
- Expansion into new therapeutic areas.
- Strategic partnerships with pharmaceutical companies.
- Geographic expansion into new markets.
- Development of next-generation oral biologics.
Threats
- Competition from established pharmaceutical companies.
- Regulatory hurdles and approval delays.
- Patent challenges and intellectual property disputes.
- Unsuccessful clinical trials.
Competitive Advantages
- Proprietary oral drug delivery technology platform.
- Patent protection for its formulations and methods.
- Clinical data demonstrating efficacy and safety.
- First-mover advantage in the oral biologics market.
About ENTXW
Entera Bio Ltd. is a biopharmaceutical company focused on the development and commercialization of orally delivered formulations of large molecule therapeutics. Founded with the goal of transforming the delivery of biologics, Entera Bio leverages its proprietary technology platform to enable the oral administration of drugs that are typically delivered via injection. The company's primary focus is on addressing unmet needs in bone and metabolic disorders, with a lead product candidate targeting osteoporosis. Entera Bio's technology aims to improve patient compliance, convenience, and overall treatment outcomes by replacing injectable therapies with oral alternatives. The company's research and development efforts are centered on advancing its pipeline of oral biologics, with the goal of providing innovative solutions for patients with chronic diseases. Entera Bio's warrants, ENTXW, represent the right to purchase shares of the company's common stock, offering investors a leveraged opportunity to participate in the company's potential success. However, these warrants expired in June 2023.
What They Do
- Develops oral formulations of large molecule therapeutics.
- Focuses on addressing unmet needs in bone and metabolic disorders.
- Utilizes a proprietary technology platform to enable oral delivery of biologics.
- Aims to replace injectable therapies with oral alternatives.
- Conducts research and development to advance its pipeline of oral biologics.
- Targets osteoporosis with its lead product candidate.
Business Model
- Develops and patents oral drug delivery technology.
- Conducts clinical trials to demonstrate safety and efficacy.
- Seeks regulatory approval from health authorities.
- May partner with pharmaceutical companies for commercialization.
- Generates revenue through product sales and licensing agreements.
Industry Context
Entera Bio operates within the competitive pharmaceutical industry, specifically targeting the oral delivery of large molecule therapeutics. The market for oral biologics is driven by the desire for more convenient and patient-friendly drug delivery methods. The osteoporosis market, in particular, represents a significant opportunity for Entera Bio, given the large patient population and the limitations of existing injectable therapies. Competitors are working on alternative delivery methods and novel treatments for bone and metabolic disorders. The industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition.
Key Customers
- Patients with osteoporosis and other bone disorders.
- Physicians who prescribe treatments for these conditions.
- Pharmacies that dispense medications.
- Hospitals and clinics that administer therapies.
Financials
Chart & Info
Entera Bio Ltd. WT EXP 062723 (ENTXW) stock price: Price data unavailable
Latest News
No recent news available for ENTXW.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ENTXW.
Price Targets
Wall Street price target analysis for ENTXW.
MoonshotScore
What does this score mean?
The MoonshotScore rates ENTXW's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: None
CEO title
Due to the absence of CEO information, this section remains incomplete. Typically, this section would detail the CEO's professional history, including previous roles, education, and any relevant experience in the pharmaceutical or biotechnology industries. This background helps investors assess the CEO's suitability for leading the company and executing its strategic vision.
Track Record: Due to the absence of CEO information, this section remains incomplete. A typical track record would highlight key achievements, strategic decisions, and company milestones achieved under the CEO's leadership. This provides investors with insights into the CEO's ability to drive growth and create value for shareholders.
ENTXW Healthcare Stock FAQ
What does Entera Bio Ltd. WT EXP 062723 do?
Entera Bio Ltd. is a biopharmaceutical company focused on developing and commercializing orally delivered formulations of large molecule therapeutics. Their proprietary technology aims to transform the delivery of biologics, typically administered via injection, into oral alternatives. The company's primary focus is on bone and metabolic disorders, with a lead product candidate targeting osteoporosis. The warrants, ENTXW, represented the right to purchase shares of the company's common stock, but expired in June 2023.
What do analysts say about ENTXW stock?
AI analysis is pending for ENTXW. Generally, biotechnology stocks are evaluated based on their pipeline potential, clinical trial results, and regulatory milestones. Key valuation metrics include cash burn rate, potential market size for their drugs, and probability of regulatory approval. Given the warrants expired in June 2023, there is no current analyst coverage.
What are the main risks for ENTXW?
The main risks for Entera Bio Ltd. include the inherent uncertainties of pharmaceutical development, such as unsuccessful clinical trial results and regulatory approval delays. Competition from established pharmaceutical companies and alternative treatments also poses a significant risk. Financial risks include high research and development costs and the need to raise additional capital. The warrants (ENTXW) expired in June 2023, rendering them valueless.
What are the key factors to evaluate for ENTXW?
Entera Bio Ltd. WT EXP 062723 (ENTXW) currently holds an AI score of 44/100, indicating low score. Key strength: Proprietary oral drug delivery technology.. Primary risk to monitor: Potential: Unsuccessful clinical trial results.. This is not financial advice.
How frequently does ENTXW data refresh on this page?
ENTXW prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven ENTXW's recent stock price performance?
Recent price movement in Entera Bio Ltd. WT EXP 062723 (ENTXW) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary oral drug delivery technology.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider ENTXW overvalued or undervalued right now?
Determining whether Entera Bio Ltd. WT EXP 062723 (ENTXW) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying ENTXW?
Before investing in Entera Bio Ltd. WT EXP 062723 (ENTXW), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis pending.
- Information based on available financial data and company description.
- The warrants (ENTXW) expired in June 2023.